Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.

Ayalew Tefferi, Ross L. Levine, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

Original languageEnglish (US)
Pages (from-to)114-119
Number of pages6
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume15
Issue number1 Suppl
StatePublished - 2009

Fingerprint

Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Systemic Mastocytosis
Platelet-Derived Growth Factor beta Receptor
Neoplasms
Mutation
Gene Fusion
Oncogene Proteins
Mutant Proteins
Oncogenes
Lymphoma
Leukemia
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2526a527b1a84473aaa113297737f7d7,
title = "Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.",
abstract = "Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.",
author = "Ayalew Tefferi and Levine, {Ross L.} and Hagop Kantarjian",
year = "2009",
language = "English (US)",
volume = "15",
pages = "114--119",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.

AU - Tefferi, Ayalew

AU - Levine, Ross L.

AU - Kantarjian, Hagop

PY - 2009

Y1 - 2009

N2 - Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

AB - Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

UR - http://www.scopus.com/inward/record.url?scp=60849136930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849136930&partnerID=8YFLogxK

M3 - Article

C2 - 19147089

VL - 15

SP - 114

EP - 119

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 Suppl

ER -